Table 2.
Risk of first positive SARS-CoV-2 test, vaccination, hospitalization and death in CVID patients vs. population controls in Denmark, March 1, 2020 – May 1, 2022.
| CVID patients | Observation time | Controls | Observation time | Unadjusted IRR 195% en | Adjusted IRR* 195% en | |
|---|---|---|---|---|---|---|
| All individuals | N | PYR | N | PYR | ||
| First occurrence of a positive test for COVID-191 | 164 | 494 | 1,114 | 4,067 | 1.3 (1.1-1.5) | 1.6 (1.3-1.9) |
| Second occurrence of a positive test for COVID-191 | 15 | 56 | 51 | 390 | 2.1(1.2-3.8) | 2.1(1.1-4.1) |
| Hospital contact1 | 45 | 539 | 16 | 4,463 | 24.5 (13.9- 43.4) | 20.3 (10.6- 38.7) |
| Hospitalization with severe COVID-191 | 4 | 551 | 2 | 4,469 | 16.2 (3.0-88.5) | 10.7 (1.5-78.5) |
| SARS-CoV-2 positive patients only | PYR | PYR | IRR | aIRR** | ||
| Time to hospitalization > 24 hours after a positive test2 | 11 | 32 | 17 | 239 | 4.8 (2.2-10.2) | 2.6 (1.1-6.1) |
| Death following a positive SARS-CoV-2 test1 | 1 | 242 | 4 | 35 | 1.7 (0.2-15.2) | 0.4 (0.0-3.8) |
CVID, Common variable immunodeficiency; PY, Person years of follow-up; incidence Rate Ratio, Adjusted NR: 9%: Confidence interval.
1Calendar time as time axis time since SARS-CoV 2 positive as time axis.
*Adjusted for charlsons Comorbidity index, categorised.
**Adjusted for age, gender and Charlson's Comorbidity Index.